Longevity & AgingNew Blood Test Outperforms PSA at Catching Dangerous Prostate Cancers
A multicomponent blood test called Stockholm3 significantly outperforms standard PSA screening for detecting dangerous prostate cancers. Analyzing data from over 12,000 men in a Swedish randomized trial, researchers found Stockholm3 caught 90% of clinically significant prostate cancers compared to just 74% with PSA alone, while keeping false-positive rates nearly identical. The test combines PSA with additional protein biomarkers, a polygenic risk score, and clinical variables. Per 1,000 men screened, Stockholm3 found about 6 more cancers while missing far fewer cases. Researchers say the test supports a more precise, risk-adapted screening approach that reduces unnecessary biopsies without sacrificing detection of cancers that truly need treatment.
